Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide

The cytogeneticanomaly of isolated del(5q) characterizes a subgroup of patients with lower-risk myelodysplastic syndrome(MDS). In the 2016 World Health Organization classification, one additional karyotypic abnormality (except −7 or del7q) can be present in such patients.[1][1] Median survival